FDA Approves Moderna’s mRNA Flu Vaccine for Adults 50 and Over
The Food and Drug Administration has approved Moderna's first mRNA-based flu vaccine, making it available to adults aged 50 and over. The new vaccine is reportedly more effective than traditional flu shots and can be developed more quickly. While Medicare…
Philadelphia, PA, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s first messenger RNA (mRNA) based influenza vaccine. This new vaccine is now available for adults aged 50 and older.
The mRNA technology employed in this vaccine is reportedly more effective compared to traditional flu shots. Additionally, it is noted for its capacity for quicker development, a crucial factor in responding to rapidly evolving influenza strains.
Regarding cost and coverage, Medicare is stated to cover the new vaccine. However, information on coverage for individuals with other insurance plans was not provided.
The approval marks a significant development, especially considering past criticisms that have been leveled against mRNA technology. Despite this history, medical experts have expressed optimism about the vaccine’s potential impact on combating seasonal and potentially pandemic influenza outbreaks.
Details regarding the specific efficacy rates compared to traditional vaccines or the timeline for wider availability beyond the initial target demographic were not included in the information provided.
Story summarized from the original created by Rachel Roubein on www.inquirer.com, see more information here.
